T-type calcium channel antagonism produces antipsychotic-like effects and reduces stimulant-induced glutamate release in the nucleus accumbens of rats

Neuropharmacology

Volumn 62, Issue 3, 2012, Pages 1413-1421

  Uslaner, Jason M ^a   Smith, Sean M ^a   Huszar, Sarah L ^a   Pachmerhiwala, Rashida ^a   Hinchliffe, Richard M ^a   Vardigan, Joshua D ^a   Nguyen, Shannon J ^a   Surles, Nathan O ^a   Yao, Lihang ^a   Barrow, James C ^a   Uebele, Victor N ^a   Renger, John J ^a   Clark, Janet ^a   Hutson, Pete H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Amphetamine; c fos; Conditioned avoidance responding; Dopamine; MK 801; Psychosis

Indexed keywords

AMPHETAMINE; CALCIUM CHANNEL AFFECTING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIZOCILPINE; DOPAMINE; GLUTAMIC ACID; HALOPERIDOL; MESSENGER RNA; OLANZAPINE; PROTEIN C FOS; TTA A2; TTA P1; TTA Q6; UNCLASSIFIED DRUG;

AMINO ACID SYNTHESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPSYCHOTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DOPAMINE RELEASE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NERVE CELL NETWORK; NONHUMAN; NUCLEOTIDE SEQUENCE; NUCLEUS ACCUMBENS; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOMOTOR ACTIVITY; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ROTAROD TEST; SCHIZOPHRENIA;

AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZENEACETAMIDES; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, T-TYPE; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTAMIC ACID; MALE; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR;

EID: 84856107972     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.11.015     Document Type: Article

References (59)

1. J. Arnt Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of d-amphetamine Eur. J. Pharmacol. 283 1995 55 62
2. J. Arnt, T. Skarsfeldt, and J. Hyttel Differentiation of classical and novel antipsychotics using animal models Int. Clin. Psychopharmacol. 12 Suppl 1 1997 S9 S17
3. H. Ascher-Svanum, A.W. Nyhuis, V. Stauffer, B.J. Kinon, D.E. Faries, G.A. Phillips, K. Schuh, A.G. Awad, R. Keefe, and D. Naber Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives Curr. Med. Res. Opin. 26 2010 2403 2410
4. A. Badiani, M.M. Oates, H.E. Day, S.J. Watson, H. Akil, and T.E. Robinson Amphetamine-induced behavior, dopamine release, and c-fos mRNA expression: modulation by environmental novelty J. Neurosci. 18 1998 10579 10593 (Pubitemid 29016576)
5. Barrow, J.C.; Bieber, K.A.S.; Cube, R.V.; Mattern, M.C.; Reger, T.S.; Shu, Y.; 2007. Pyridyl amide T-type calcium channel antagonists. US Patent WO 2007120729.
6. J.C. Barrow, K.E. Rittle, T.S. Reger, Z.Q. Yanq, P. Bondiskey, G.B. McGaughey, M.G. Bock, G.D. Hartman, C. Tang, J.E. Ballard, Y. Kuo, T. Prueksaritanont, C.E. Nuss, S.M. Doran, S.V. Fox, S.L. Garson, R.L. Kraus, Y. Li, M.J. Marino, V.K. Graufelds, V.N. Uebele, and J.J. Renger Discovery of 4,4-disubstituted quinazolin-2-ones as T-type calcium channel antagonists ACS Med. Chem. Lett. 1 2010 75 79
7. H.W. Berendse, and H.J. Groenewegen Organization of the thalamostriatal projections in the rat, with special emphasis on the ventral striatum J. Comp. Neurol. 299 1990 187 228 (Pubitemid 20313479)
8. V. Bisagno, M. Raineri, V. Peskin, S.I. Wikinski, O.D. Uchitel, R.R. Llinas, and F.J. Urbano Effects of T-type calcium channel blockers on cocaine-induced hyperlocomotion and thalamocortical GABAergic abnormalities in mice Psychopharmacology (Berl.) 2010
9. L.H. Burns, B.J. Everitt, A.E. Kelley, and T.W. Robbins Glutamate-dopamine interactions in the ventral striatum: role in locomotor activity and responding with conditioned reinforcement Psychopharmacology (Berl.) 115 1994 516 528 (Pubitemid 24248443)
10. J. Cartmell, J.A. Monn, and D.D. Schoepp Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine Psychopharmacology (Berl.) 148 2000 423 429 (Pubitemid 30169761)
11. J. Cartmell, J.A. Monn, and D.D. Schoepp The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing Eur. J. Pharmacol. 400 2000 221 224 (Pubitemid 30438730)
12. J. Cartmell, J.A. Monn, and D.D. Schoepp Tolerance to the motor impairment, but not to the reversal of PCP-induced motor activities by oral administration of the mGlu2/3 receptor agonist, LY379268 Naunyn Schmiedebergs Arch. Pharmacol. 361 2000 39 46 (Pubitemid 30064652)
13. K.H. Choi, and H. Rhim Inhibition of recombinant Ca(v)3.1 (alpha(1G)) T-type calcium channels by the antipsychotic drug clozapine Eur. J. Pharmacol. 626 2010 123 130
14. B. Ellenbroek, and A.R. Cools The paw test: an animal model for neuroleptic drugs which fulfils the criteria for pharmacological isomorphism Life Sci. 42 1988 1205 1213 (Pubitemid 18064273)
15. B.A. Ellenbroek, B.W. Peeters, W.M. Honig, and A.R. Cools The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs Psychopharmacology (Berl.) 93 1987 343 348 (Pubitemid 17160658)
16. J.J. Enyeart, B.A. Biagi, and B. Mlinar Preferential block of T-type calcium channels by neuroleptics in neural crest-derived rat and human C cell lines Mol. Pharmacol. 42 1992 364 372 (Pubitemid 23026172)
17. K.T. Harker, and I.Q. Whishaw Place and matching-to-place spatial learning affected by rat inbreeding (Dark-Agouti, Fischer 344) and albinism (Wistar, Sprague-Dawley) but not domestication (wild rat vs. Long-Evans, Fischer-Norway) Behav. Brain Res. 134 2002 467 477 (Pubitemid 34918603)
18. Y. Hori, H. Takeda, M. Tsuji, and T. Matsumiya Differentiation of the inhibitory effects of calcium antagonists on abnormal behaviors induced by methamphetamine or phencyclidine Pharmacology 56 1998 165 174 (Pubitemid 28112384)
19. Y. Hu, K.M. Mitchell, F.N. Albahadily, E.K. Michaelis, and G.S. Wilson Direct measurement of glutamate release in the brain using a dual enzyme-based electrochemical sensor Brain Res. 659 1994 117 125 (Pubitemid 24292852)
20. J.R. Huguenard Low-threshold calcium currents in central nervous system neurons Annu. Rev. Physiol. 58 1996 329 348 (Pubitemid 26106724)
21. D.C. Javitt Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia Hillside J. Clin. Psychiatry 9 1987 12 35
22. S. Kapur, and D. Mamo Half a century of antipsychotics and still a central role for dopamine D2 receptors Prog. Neuropsychopharmacol. Biol. Psychiatry 27 2003 1081 1090 (Pubitemid 37464954)
23. J.H. Kim, and P. Vezina Activation of metabotropic glutamate receptors in the rat nucleus accumbens increases locomotor activity in a dopamine-dependent manner J. Pharmacol. Exp. Ther. 283 1997 962 968 (Pubitemid 27514661)
24. B.J. Kinon LY2140023 Monohydrate: An Agonist at the mGlu2/3 Receptor for the Treatment of Schizophrenia 2009 International Congress on Schizophrenia Research San Diego
25. R.L. Kraus, Y. Li, Y. Gregan, A.L. Gotter, V.N. Uebele, S.V. Fox, S.M. Doran, J.C. Barrow, Z.Q. Yang, T.S. Reger, K.S. Koblan, and J.J. Renger In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice J. Pharmacol. Exp. Ther. 335 2010 409 417
26. J.H. Krystal, L.P. Karper, J.P. Seibyl, G.K. Freeman, R. Delaney, J.D. Bremner, G.R. Heninger, M.B. Bowers Jr.; and D.S. Charney Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch. Gen. Psychiatry 51 1994 199 214 (Pubitemid 24081509)
27. A.C. Lahti, M.A. Weiler, B.A. Tamara Michaelidis, A. Parwani, and C.A. Tamminga Effects of ketamine in normal and schizophrenic volunteers Neuropsychopharmacology 25 2001 455 467 (Pubitemid 32830950)
28. K.H. Lee, K. Kristic, R. van Hoff, F.L. Hitti, C. Blaha, B. Harris, D.W. Roberts, and J.C. Leiter High-frequency stimulation of the subthalamic nucleus increases glutamate in the subthalamic nucleus of rats as demonstrated by in vivo enzyme-linked glutamate sensor Brain Res. 1162 2007 121 129 (Pubitemid 47088377)
29. J.A. Lieberman, T.S. Stroup, J.P. McEvoy, M.S. Swartz, R.A. Rosenheck, D.O. Perkins, R.S. Keefe, S.M. Davis, C.E. Davis, B.D. Lebowitz, J. Severe, and J.K. Hsiao Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N. Engl. J. Med. 353 2005 1209 1223 (Pubitemid 41345943)
30. B. Moghaddam, and B.W. Adams Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats Science 281 1998 1349 1352 (Pubitemid 28406826)
31. S. Natesan, G.E. Reckless, K.B. Barlow, J.N. Nobrega, and S. Kapur Amisulpride the 'atypical' atypical antipsychotic-comparison to haloperidol, risperidone and clozapine Schizophr Res. 105 2008 224 235
32. S. Natesan, G.E. Reckless, J.N. Nobrega, P.J. Fletcher, and S. Kapur Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models Neuropsychopharmacology 31 2006 1854 1863
33. B. Nilius, K. Talavera, and A. Verkhratsky T-type calcium channels: the never ending story Cell Calcium 40 2006 81 88 (Pubitemid 43942293)
34. S.T. Patil, L. Zhang, F. Martenyi, S.L. Lowe, K.A. Jackson, B.V. Andreev, A.S. Avedisova, L.M. Bardenstein, I.Y. Gurovich, M.A. Morozova, S.N. Mosolov, N.G. Neznanov, A.M. Reznik, A.B. Smulevich, V.A. Tochilov, B.G. Johnson, J.A. Monn, and D.D. Schoepp Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial Nat. Med. 13 2007 1102 1107 (Pubitemid 47517511)
35. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates second ed. 1982 Academic San Diego
36. A.L. Pehrson, and B. Moghaddam Impact of metabotropic glutamate 2/3 receptor stimulation on activated dopamine release and locomotion Psychopharmacology (Berl.) 211 2010 443 455
37. P. Popoli, A. Pezzola, and A. Scotti de Carolis Influence of non-L-type calcium channel antagonists on phencyclidine-induced effects in rats Life Sci. 52 1993 2055 2061
38. G.T. Prusky, K.T. Harker, R.M. Douglas, and I.Q. Whishaw Variation in visual acuity within pigmented, and between pigmented and albino rat strains Behav. Brain Res. 136 2002 339 348 (Pubitemid 35333249)
39. G.V. Rebec, E.E. Peirson, F.A. McPherson, and K. Brugge Differential sensitivity to amphetamine following long-term treatment with clozapine or haloperidol Psychopharmacology (Berl.) 77 1982 360 366 (Pubitemid 12061702)
40. A. Rex, J.P. Voigt, C. Gustedt, S. Beckett, and H. Fink Anxiolytic-like profile in Wistar, but not Sprague-Dawley rats in the social interaction test Psychopharmacology (Berl.) 177 2004 23 34 (Pubitemid 40109911)
41. A.N. Samaha, P. Seeman, J. Stewart, H. Rajabi, and S. Kapur "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time J. Neurosci. 27 2007 2979 2986 (Pubitemid 46438984)
42. C.M. Santi, F.S. Cayabyab, K.G. Sutton, J.E. McRory, J. Mezeyova, K.S. Hamming, D. Parker, A. Stea, and T.P. Snutch Differential inhibition of T-type calcium channels by neuroleptics J. Neurosci. 22 2002 396 403 (Pubitemid 34049077)
43. C. Schlumberger, D. Schafer, C. Barberi, L. More, J. Nagel, M. Pietraszek, W.J. Schmidt, and W. Danysz Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition Behav. Pharmacol. 20 2009 56 66
44. T.F. Seeger, P.A. Seymour, A.W. Schmidt, S.H. Zorn, D.W. Schulz, L.A. Lebel, S. McLean, V. Guanowsky, H.R. Howard, and J.A. Lowe 3rd Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity J. Pharmacol. Exp. Ther. 275 1995 101 113
45. R.C. Smith, and J.M. Davis Behavioral supersensitivity to apomorphine and amphetamine after chronic high dose haloperidol treatment Psychopharmacol. Commun. 1 1975 285 293
46. R.C. Smith, and J.M. Davis Behavioral evidence for supersensitivity after chronic administration of haloperidol, clozapine, and thioridazine Life Sci. 19 1976 725 731
47. C.J. Swanson, and D.D. Schoepp The group II metabotropic glutamate receptor agonist (-)-2-oxa-4-aminobicyclo[3.1.0.]hexane-4,6-dicarboxylate (LY379268) and clozapine reverse phencyclidine-induced behaviors in monoamine-depleted rats J. Pharmacol. Exp. Ther. 303 2002 919 927 (Pubitemid 35424372)
48. E.M. Talley, L.L. Cribbs, J.H. Lee, A. Daud, E. Perez-Reyes, and D.A. Bayliss Differential distribution of three members of a gene family encoding low voltage-activated (T-type) calcium channels J. Neurosci. 19 1999 1895 1911 (Pubitemid 29133368)
49. V.N. Uebele, A.L. Gotter, C.E. Nuss, R.L. Kraus, S.M. Doran, S.L. Garson, D.R. Reiss, Y. Li, J.C. Barrow, T.S. Reger, Z.Q. Yang, J.E. Ballard, C. Tang, J.M. Metzger, S.P. Wang, K.S. Koblan, and J.J. Renger Antagonism of T-type calcium channels inhibits high-fat diet-induced weight gain in mice J. Clin. Invest. 119 2009 1659 1667
50. V.N. Uebele, C.E. Nuss, S.V. Fox, S.L. Garson, R. Cristescu, S.M. Doran, R.L. Kraus, V.P. Santarelli, Y. Li, J.C. Barrow, Z.Q. Yang, K.A. Schlegel, K.E. Rittle, T.S. Reger, R.A. Bednar, W. Lemaire, F.A. Mullen, J.E. Ballard, C. Tang, G. Dai, O.B. McManus, K.S. Koblan, and J.J. Renger Positive allosteric interaction of structurally diverse T-type calcium channel antagonists Cell Biochem. Biophys. 55 2009 81 93
51. J.M. Uslaner, S.M. Smith, S.L. Huszar, R. Pachmerhiwala, R.M. Hinchliffe, J.D. Vardigan, and P.H. Hutson Combined administration of an mGlu2/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants Psychopharmacology (Berl.) 206 2009 641 651
52. J.M. Uslaner, J.D. Vardigan, J.M. Drott, V.N. Uebele, J.J. Renger, A. Lee, Z. Li, A.D. Le, and P.H. Hutson T-Type calcium channel antagonism decreases motivation for nicotine and blocks nicotine- and cue-induced reinstatement for a response previously reinforced with nicotine Biol. Psychiatry 2010
53. P. Vezina, and J.H. Kim Metabotropic glutamate receptors and the generation of locomotor activity: interactions with midbrain dopamine Neurosci. Biobehav. Rev. 23 1999 577 589 (Pubitemid 29086926)
54. M.L. Wadenberg, and P.B. Hicks The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci. Biobehav. Rev. 23 1999 851 862 (Pubitemid 29458891)
55. A.R. West, S.B. Floresco, A. Charara, J.A. Rosenkranz, and A.A. Grace Electrophysiological interactions between striatal glutamatergic and dopaminergic systems Ann. N. Y. Acad. Sci. 1003 2003 53 74 (Pubitemid 38083045)
56. C.I. Wright, and H.J. Groenewegen Patterns of convergence and segregation in the medial nucleus accumbens of the rat: relationships of prefrontal cortical, midline thalamic, and basal amygdaloid afferents J. Comp. Neurol. 361 1995 383 403
57. E.Q. Wu, H.G. Birnbaum, L. Shi, D.E. Ball, R.C. Kessler, M. Moulis, and J. Aggarwal The economic burden of schizophrenia in the United States in 2002 J. Clin. Psychiatry 66 2005 1122 1129 (Pubitemid 41442278)
58. Z.Q. Yang, J.C. Barrow, W.D. Shipe, K.A. Schlegel, Y. Shu, F.V. Yang, C.W. Lindsley, K.E. Rittle, M.G. Bock, G.D. Hartman, V.N. Uebele, C.E. Nuss, S.V. Fox, R.L. Kraus, S.M. Doran, T.M. Connolly, C. Tang, J.E. Ballard, Y. Kuo, E.D. Adarayan, T. Prueksaritanont, M.M. Zrada, M.J. Marino, V.K. Graufelds, A.G. DiLella, I.J. Reynolds, H.M. Vargas, P.B. Bunting, R.F. Woltmann, M.M. Magee, K.S. Koblan, and J.J. Renger Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels J. Med. Chem. 51 2008 6471 6477
59. Y. Zhang, R.R. Llinas, and J.E. Lisman Inhibition of NMDARs in the nucleus reticularis of the thalamus produces delta frequency bursting Front. Neural Circuits 3 2009 20